|Articles|November 8, 2015

NYU Doctors Explain DCIS

Last month, we got the chance to discuss DCIS with three doctors from NYU Cancer Center: Dr. Deborah Axelrod, Dr. Julia Smith, and Dr. David Kleinberg.

They explain what DCIS is, discuss public trials and future directions for DCIS, and address some current controversies around the diagnosis.

Listen to the talk here:

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!

Related Content

Zervyteg improved responses and was safe in steroid- and Jakafi-resistant acute graft-versus-host disease affecting the GI tract in a phase 3 trial.

Zervyteg Shows Strong Responses in Acute Graft-Versus-Host Disease

ByAndrea Eleazar, MHS

December 8th 2025

In a direct comparison, Jaypirca matched Imbruvica in response and suggested a progression-free survival benefit for patients with CLL/SLL.

Updated Data Reinforce Treatment With Jaypirca in CLL/SLL

ByJason Broderick

December 8th 2025

Dr. Robert Orlowski, chairman, Ad Interim; director of Myeloma; and professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston.

Single-Drug Approach Explored for Newly Diagnosed Multiple Myeloma

ByDr. Robert Orlowski

December 8th 2025

Georgia Hurst is a fierce patient advocate for those with Lynch syndrome. Catch up on all of Georgia's blogs here!

What I Want You to Know about Lynch Syndrome

ByGeorgia Hurst

December 8th 2025

Jaypirca Matches Imbruvica's Effectiveness for CLL, With Hints of Long-Term Benefit

ByJason M Broderick

December 7th 2025

NYU Doctors Explain DCIS

Newsletter

Related Content

Zervyteg Shows Strong Responses in Acute Graft-Versus-Host Disease

Updated Data Reinforce Treatment With Jaypirca in CLL/SLL

Single-Drug Approach Explored for Newly Diagnosed Multiple Myeloma

What I Want You to Know about Lynch Syndrome

Jaypirca Matches Imbruvica's Effectiveness for CLL, With Hints of Long-Term Benefit

Trending on CURE

A New Option Without Traditional Chemotherapy for Ph+ ALL

Azacitidine Plus Venclexta Superior to Chemo in Acute AML

Jaypirca Matches Imbruvica's Effectiveness for CLL, With Hints of Long-Term Benefit

First Annual Blood Cancer Heroes Honors Leaders, Advocates and Survivors

Elrexfio Maintains Responses in Elderly, Frail Patients With Multiple Myeloma